Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The activation of the MAPK and PI3K/AKT/mTOR pathways is implicated in the majority of cancers. Activating mutations in both of these pathways has been described in colorectal cancer (CRC), thus indicating their potential as therapeutic targets. This study evaluated the combination of a PI3K/mTOR inhibitor (PF-04691502/PF-502) in combination with a MEK inhibitor (PD-0325901/PD-901) in CRC cell lines and patient-derived CRC tumor xenograft models (PDTX). MATERIALS AND METHODS: The anti-proliferative effects of PF-502 and PD-901 were assessed as single agents and in combination against a panel of CRC cell lines with various molecular backgrounds. Synergy was evaluated using the Bliss Additivity method. In selected cell lines, we investigated the combination effects on downstream effectors by immunoblotting. The combination was then evaluated in several fully genetically annotated CRC PDTX models. RESULTS: The in vitro experiments demonstrated a wide range of IC50 values for both agents against a cell line panel. The combination of PF-502 and PD-901 demonstrated synergistic anti-proliferative activity with Bliss values in the additive range. As expected, p-AKT and p-ERK were downregulated by PF-502 and PD-901, respectively. In PDTX models, following a 30-day exposure to PF-502, PD-901 or the combination, the combination demonstrated enhanced reduction in tumor growth as compared to either single agent regardless of KRAS or PI3K mutational status. CONCLUSIONS: The combination of a PI3K/mTOR and a MEK inhibitor demonstrated enhanced anti-proliferative effects against CRC cell lines and PDTX models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, results from several preclinical and clinical studies indicate that dual pharmacological targeting of MAPK and PI3K pathways may be an effective strategy to inhibit the growth of CRC cells, regardless of KRAS or PI3K mutational status [127,128,129,130,131].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [131]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788 · cited 1×
“agents have been developed that target EGFR, RAS, RAF, or MEK, many of which are in clinical trials and some of which are already approved [14].”
BackgroundmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“Additionally, it is thought that the RAS-RAF-MEK signaling axis may act as a compensatory mechanism with inhibition of the PI3K-AKT-mTOR pathway, and vice versa [18,19].”
BackgroundDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 15×
“And, the CUCRC042 (KRAS G13D) model was relatively unresponsive to all treatments (Figure 7D).”
BackgroundInfluentialTOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924 · cited 1×
“Cell growth is one of the primary functions governed by mTOR; activation of mTOR via the PI3K/AKT pathway is critical for the cell in balance nutrient uptake and growth, and aberrant hyperactivation of this pathway contributes to tumorigenesis [6,7].”
BackgroundPI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845 · cited 1×
“PI3K phosphorylates the 3hydroxyl group of phosphatidylinositol, participating in a variety of signaling pathways important for cancer such as proliferation, differentiation, chemotaxis, survival, trafficking, and glucose homeostasis [2,3].”
BackgroundTargeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290 · cited 1×
“Because of its diverse cellular function, the PI3K axis is highly implicated in human cancers; up to 30% of all human cancers have a mutation in a PI3K pathway component [4].”
Background
Cited by
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
Temraz, S., Mukherji, D., & Shamseddine, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922976 · Cited by 117
“Similarly, Pitt et al. demonstrated synergistic anti-proliferative activity with the combination of PI3K/mTOR inhibitor PF-502 and the MEK1/2 inhibitor PD-901 [45].”
BackgroundWainberg, Z. A., Alsina, M., Soares, H. P., Braña, I., Britten, C. D., Del Conte, G., Ezeh, P., Houk, B., Kern, K. A., Leong, S., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0530-5 · Cited by 98
Self-citationMossenta, M., Busato, D., Bo, M. D., & Toffoli, G. (2020) · Cancers · doi:10.3390/cancers12061668 · Cited by 99
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Indeed, results from several preclinical and clinical studies indicate that dual pharmacological targeting of MAPK and PI3K pathways may be an effective strategy to inhibit the growth of CRC cells, regardless of KRAS or PI3K mutational status [127–131].”
Recent contributions of quinolines to antimalarial and anticancer drug discovery research
de Walle, T. V., Cools, L., Mangelinckx, S., & D’hooghe, M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113865 · Cited by 86
Mohan, S., Broek, R. V., Shah, S., Eytan, D. F., Pierce, M., Carlson, S. G., Coupar, J. F., Zhang, J., Cheng, H. W., Chen, Z., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3377 · Cited by 75
“In addition, the effectiveness of combined MEK and PI3K/mTOR inhibition in colorectal cancer reduction is not dependent on KRAS or PIK3CAmutational status (43).”
Ma, X., Lv, X., & Zhang, J. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.049 · Cited by 77
Wu, L. Y., Maachani, U. B., Schweitzer, M. E., Singh, R., Wang, M., Chang, R. Y., & Souweidane, M. M. (2017) · Translational Oncology · doi:10.1016/j.tranon.2016.12.008 · Cited by 69
Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer
Beadnell, T. C., Nassar, K. W., Rose, M. M., Clark, E. G., Danysh, B. P., Hofmann, M.-C. C., Pozdeyev, N. V., & Schweppe, R. E. (2018) · Oncogenesis · doi:10.1038/s41389-017-0015-5 · Cited by 63
Gharib, E., & Robichaud, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179463 · Cited by 65
Li, J., Gao, Z., Zhao, D., Zhang, L., Qiao, X., Zhao, Y., Ding, H., Zhang, P., Lu, J., Liu, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0484 · Cited by 51
Bian, Y., Han, J., Kannabiran, V. R., Mohan, S., Cheng, H. W., Friedman, J., Zhang, L., Waes, C. V., & Chen, Z. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.10745 · Cited by 48
Toren, P., Kim, S., Johnson, F. D., & Zoubeidi, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152861 · Cited by 35
Neomorphic mutations create therapeutic challenges in cancer
Takiar, V., Ip, C. K. M., Gao, M., Mills, G. B., & Cheung, L. W. T. (2016) · Oncogene · doi:10.1038/onc.2016.312 · Cited by 35
The association of aberrant expression of NLRP3 and p-S6K1 in colorectal cancer
Wang, B., Li, H., Wang, X., & Zhu, X. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152737 · Cited by 31
Hartman, S. J., Bagby, S. M., Yacob, B. W., Simmons, D. M., MacBeth, M. L., Lieu, C. H., Davis, S. L., Leal, A. D., Tentler, J. J., Diamond, J. R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642328 · Cited by 30
“Synergy was calculated from the 72 hour proliferation averages using the Bliss Additivity model as previously described (22).”
MethodSelf-citationTherapeutic Targets of KRAS in Colorectal Cancer
Rahman, S., Garrel, S., Gerber, M., Maitra, R., & Goel, S. (2021) · Cancers · doi:10.3390/cancers13246233 · Cited by 28
“A pre-clinical study supporting the above results was done by Pitt et al. where they demonstrated suppression of tumor progression in CRC cell lines and tumor xenografts models with combinatory PI3K/mTOR inhibitor PF-502 and the MEK1/2 inhibitor PD-901 [79].”
BackgroundDavis, S. L., Hartman, S. J., Bagby, S. M., Schlaepfer, M. I., Yacob, B. W., Tse, T. E., Simmons, D. M., Diamond, J. R., Lieu, C. H., Leal, A. D., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10084-7 · Cited by 28
“The Bliss Additivity model was used to calculate synergy from average proliferation at 120 h [10, 11].”
MethodSelf-citationLee, C. L., Cremona, M., Farrelly, A. M., Workman, J. A., Kennedy, S., Aslam, R., Carr, A., Madden, S. F., O’Neill, B., Hennessy, B. T., et al. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2223388 · Cited by 30
Li, C., Zhan, Y., Ma, X., Fang, H., & Gai, X. (2019) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00590-7 · Cited by 26
Taylor, H. M., Yerlioglu, D., Phen, C., Ballauff, A., Nedelkopoulou, N., Spier, I., Loverdos, I., Busoni, V., Heise, J., Dale, P., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab094 · Cited by 28
“Phosphoinositol-3-kinase (PI3K)–AKT signaling and the bone morphogenetic protein (BMP) pathway control epithelial and mesenchymal crosstalk and maintain epithelial homeostasis.”
BackgroundInfluentialBagby, S. M., Messersmith, W. A., Pitts, T. M., Capasso, A., Varella-Garcia, M., Klauck, P. J., Kim, J., Tan, A. C., Eckhardt, S. G., Tentler, J. J., et al. (2016) · Journal of Visualized Experiments · doi:10.3791/54393 · Cited by 27
Self-citationBurmi, R. S., Maginn, E. N., Gabra, H., Stronach, E. A., & Wasan, H. S. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1504718 · Cited by 23
“However, these alone do not appear to be absolute predictive markers of response.(23-29) Defining the cell death pathways”
BackgroundCyclical Treatment of Colorectal Tumor Spheroids Induces Resistance to MEK Inhibitors
Thakuri, P. S., Luker, G. D., & Tavana, H. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.11.009 · Cited by 24
Klauck, P. J., Bagby, S. M., Capasso, A., Bradshaw‐Pierce, E. L., Selby, H. M., Spreafico, A., Tentler, J. J., Tan, A. C., Kim, J., Arcaroli, J. J., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4036-z · Cited by 21
Self-citationAnti-tumor effects of the ethanolic extract of Trichosanthes kirilowii seeds in colorectal cancer
Park, S. M., Jeon, S. K., Kim, O. H., Ahn, J. Y., Kim, C., Park, S., & Lee, J. (2019) · Chinese Medicine · doi:10.1186/s13020-019-0263-8 · Cited by 20
“reported enhanced anti-tumor activities for the dual PI3K/mTOR inhibitor PF-502 and the MEK inhibitor PD-901 when used in combination in in vitro and in vivo models of colorectal cancer [24].”
BackgroundCutshaw, G., Joshi, N., Wen, X., Quam, E., Bogatcheva, G., Hassan, N. A., Uthaman, S., Waite, J. R., Sarkar, S., Singh, B., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202410919 · Cited by 23
Cancer stem cell generation by silenced MAPK enhancing PI3K/AKT signaling
Hassan, G., Du, J., Afify, S. M., Seno, A., & Seno, M. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109742 · Cited by 19
Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer
Fernandes, M. S., Sanches, J., & Seruca, R. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_4 · Cited by 19
Bovio, F., Epistolio, S., Mozzi, A., Monti, E., Fusi, P. A., Forcella, M. E., & Frattini, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228805 · Cited by 17
Bani, N., Rahmani, F., Shakour, N., Amerizadeh, F., Khalili‐Tanha, G., Khazaei, M., Hassanian, S. M., Kerachian, M. A., Abbaszadegan, M. R., Mojarad, M., et al. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206296355240325113920 · Cited by 13
Network-based identification of biomarkers for colon adenocarcinoma
Hu, F., Wang, Q., Yang, Z., Zhang, Z., & Liu, X. (2020) · BMC Cancer · doi:10.1186/s12885-020-07157-w · Cited by 16
“demonstrated that the combination of a PI3K/mTOR and a MAPK inhibitor can enhance anti-proliferative effects against CRC cell lines [40] and Wang H.”
BackgroundThakuri, P. S., Lamichhane, A., Singh, S. K., Gupta, M., Luker, G. D., & Tavana, H. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00115 · Cited by 12
Lieu, C. H., Klauck, P. J., Henthorn, P. K., Tentler, J. J., Tan, A. C., Spreafico, A., Selby, H. M., Britt, B. C., Bagby, S. M., Arcaroli, J. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5949 · Cited by 11
“To test this, we focused on 11 KRAS mutant CRC cell lines that have been tested in our laboratory and demonstrated consistent sensitivity or resistance across four different MEK inhibitors [TAK-733, AZD6244 [19], PD-0325901 [20] and U0126 [21]] (Table 2).”
BackgroundSelf-citationRyabaya, O. O., Abramov, I. S., Khochenkov, D. A., Akasov, R., Sholina, N. V., & Prokofieva, A. A. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01089-3 · Cited by 11
Epigenetics and its Therapeutic Potential in Colorectal Cancer
Oryani, M. A., Tavasoli, A., Ghalavand, M. A., Ashtiani, R. Z., Rezaee, A., Mahmoudi, R., Golvari, H., Owrangi, S., & Soleymani-Goloujeh, M. (2022) · Epigenomics · doi:10.2217/epi-2022-0067 · Cited by 10
Haagensen, E. J., Thomas, H. D., Schmalix, W. A., Payne, A. C., Kevorkian, L., Allen, R. A., Bevan, P., Maxwell, R. J., & Newell, D. R. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3186-4 · Cited by 11
“Cell signalling studies showed that the single agent PI3K inhibitor WX-037 caused a concentration-dependent reduction in AKT and S6 phosphorylation, which was generally enhanced by the MEK inhibitor WX-554, but that 4EBP1 phosphorylation was not inhibited, consistent with the results of published studies using pan cla…”
ResultFukumoto, S., Kanbara, K., & Neo, M. (2018) · Acta Histochemica · doi:10.1016/j.acthis.2018.01.002 · Cited by 8
Fan, F., Ghosh, S., Powell, R. T., Roszik, J., Park, Y., Sobieski, M. M., Sorokin, A. V., STEPHAN, C. C., Kopetz, S., Ellis, L. M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281063 · Cited by 10
“Thus, multiple studies have examined the efficacy of combining MEK inhibitors with PI3K/AKT/mTOR [25, 47], Bcl-xL [26], CDK4/6 [27, 28], or autophagy [29–31] inhibitors in preclinical models of various tumors, including CRC.”
BackgroundMethods for environmental monitoring of pesticide exposure
Γούμενου, Μ., Renieri, E. A., Petrakis, D. E., Nathanail, A. V., Kokaraki, V., & Tsatsakis, A. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-812466-6.00013-0 · Cited by 10
Tao, Q., Fang, F., Li, J., Wang, Y., Zhao, C., Liang, J., Ma, X., & Wang, H. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02502-x · Cited by 7
Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer
Jayachandran, P., Elliott, A., Soni, S., Battaglin, F., Mittal, P., Algaze, S. D., Lo, J. H., Yang, Y., Ashouri, K., Torres, E. T. R., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03484-z · Cited by 6
“Additional early phase studies in cell lines and xenograft models continue to show the possible synergistic effect of MEKi and PI3K/mTOR inhibitors [68, 69].”
MTOR/4EBP1 signaling and MMR status in colorectal cancer: New correlations and arising perspectives
Zouki, D. N., Giannopoulou, I., Alexandrou, P. T., Karatrasoglou, E. A., Pilichos, G., Stamopoulos, K., Kanellis, T., Roupou, E., Saetta, A. A., Thymara, I., et al. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153655 · Cited by 5
Cutshaw, G., Joshi, N., Wen, X., Quam, E., Bogatcheva, G. T., Hassan, N. A., Uthaman, S., Waite, J. R., Sarkar, S., Singh, B., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202410919 · Cited by 6
Quesada, B. A. O., Khan, A. H., Zhou, S. P., Moe, M., Chen, J., Martin, E. C., Pojman, J. A., & Melvin, A. T. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c01025 · Cited by 4
Furukawa, H., Iwasaki, T., Kawaguchi, K., Sonoda, H., Kohashi, K., Yamamoto, H., Nakashima, Y., & Oda, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-25820-9 · Cited by 2
kaikavoosnejad, F., Kashani, H., Asl, K. D., Mazloumi, Z., Keyhani, A., Moosavi, S. S., Verdi, M., & Rafat, A. (2026) · Medical Oncology · doi:10.1007/s12032-026-03374-8 · Cited by 1
Nguyen, H. D., Le, T., Jung, D.-R., Jo, Y., Choi, Y., Lee, D., Lee, E., Cho, J., Park, J. Y., Seo, I., et al. (2024) · Oncology Letters · doi:10.3892/ol.2024.14720 · Cited by 1
“To address this chal‑ lenge, a combinatorial approach targeting mTOR and MAPK signaling should be considered for a more effective response to therapies (102,103).”
BackgroundTranslational Research and Genomics Driven Trials in Thyroid Cancer
Cabanillas, M. E., Schweppe, R. E., Dadu, R., Cote, G. J., Beadnell, T. C., & Hofmann, M.-C. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-91725-2_24
Current Trends in Treatment and New Generation of Trials in Thyroid Cancer
Iyer, P. C., Srour, S. A., Hofmann, M.-C. C., & Cabanillas, M. E. (2023) · Springer eBooks · doi:10.1007/978-3-031-38605-3_21
A Further Case for Targeting PRMT5 and the ERK1/2 and PI3K Pathways in CRC
Spivak, M., Pahmer, M., Delrahimnia, D., Sapir, T., & Shifteh, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110416
“Moreover, dual targeting of PRMT5 and the PI3K/mTOR or MEK/ERK pathways enhances anti-tumor efficacy, supporting the development of biomarker-guided combination strategies to improve therapeutic outcomes in CRC [36–38].”
Davis, S. L., Hartman, S. J., Bagby, S. M., Schlaepfer, M. I., Yacob, B. W., Tse, T. E., Simmons, D. M., Diamond, J. R., Lieu, C. H., Leal, A. D., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21435516
Self-citationDavis, S. L., Hartman, S. J., Bagby, S. M., Schlaepfer, M. I., Yacob, B. W., Tse, T. E., Simmons, D. M., Diamond, J. R., Lieu, C. H., Leal, A. D., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21435513
Self-citationDavis, S. L., Hartman, S. J., Bagby, S. M., Schlaepfer, M. I., Yacob, B. W., Tse, T. E., Simmons, D. M., Diamond, J. R., Lieu, C. H., Leal, A. D., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21435510
Self-citationBindingDB (2024) · UC San Diego · doi:10.7270/q24f1vx5
Metadata
- Authors
- Pitts, T. M., Newton, T. P., Bradshaw-Pierce, E. L., Addison, R., Arcaroli, J. J., Klauck, P. J., Bagby, S. M., Hyatt, S. L., Purkey, A., Tentler, J. J., Tan, A. C., Messersmith, W. A., Eckhardt, S. G., & Leong, S.
- Affiliations
- University of Colorado Cancer Center (US)
- University of Colorado Anschutz (US)
- Corresponding author
- Pitts, Todd M.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-11-17
- Volume
- 9
- Issue
- 11
- Pages
- e113037
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4234626
- OpenAlex
- W2020016981
- Cited by
- 54
- References
- 53
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 5 · 2021: 6 · 2020: 7 · 2019: 3 · 2018: 7 · 2017: 4 · 2016: 4 · 2015: 4
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Pfizer
- Cancer Center, University of Colorado (P30 CA046934, CA046934)
- National Cancer Institute (P30CA046934)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- colorectal cancer, PI3K/mTOR inhibition, MEK inhibition, combination therapy, MAPK signaling, PI3K/AKT/mTOR pathway, patient-derived xenografts, drug synergy, KRAS mutation, PI3K mutations, Akt phosphorylation, ERK1/2 phosphorylation, antiproliferative activity
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Animals, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Diphenylamine, Drug Synergism, Female, Humans, Mice, Nude, Immunoblotting, Colorectal Neoplasms, Signal Transduction, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.